| x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 |
|---|----------------------------------------------------------------------------------------|

|  | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 |
|----------|-----------------------------------------------------------------------------------------|

|                                                          |   |                                |
|---------------------------------------------------------------|--------|-------------------------------------|
| Nevada                                                        |   | 91-1835664                          |
| (State or Other Jurisdiction ofIncorporation or Organization) |   | (I.R.S. EmployerIdentification No.) |
|                                                          |   |
| 555 Heritage DriveJupiter, Florida                            |   | 33458                               |
| (Address of Principal Executive Offices)                      |   | (Zip Code)                          |
|                                                          |   |                                |

|                    |   |                                                   |   |                      |   |     |
|-------------------------|--------|--------------------------------------------------------|--------|---------------------------|--------|----------|
| Large accelerated filer |   |                                                |   | Accelerated filer         |   |  |
|                    |   |                                                   |   |
| Non-accelerated filer   |   |  (Do not check if a smaller reporting company) |   | Smaller reporting company |   | x        |

----

----

| Exhibit |  Note | Description                                                                                                                                                                                                                                                                 |
|---------|------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.1    |  (1)  | Research and Development Agreement, dated as of March 19, 2014, between BioRestorative Therapies, Inc. and Rohto Pharmaceutical Co., Ltd *                                                                                                                                  |
| 10.2    |  (1)  | Research Agreement, dated as of March 24, 2014, between Pfizer Inc. and BioRestorative Therapies, Inc. *                                                                                                                                                                    |
| 10.3    |  (2)  | Promissory Note, dated May 7, 2014, issued by Stem Cell Cayman Ltd. in the principal amount of $500,000                                                                                                                                                                     |
| 10.4    |  (2)  | Amendment No. One, dated as of May 9, 2014, to Research Agreement, dated June 15, 2012, between BioRestorative Therapies, Inc. and the University of Utah                                                                                                                   |
| 31.1    |  (1)  | Chief Executive Officer Certification                                                                                                                                                                                                                                       |
| 31.2    |  (1)  | Chief Financial Officer Certification                                                                                                                                                                                                                                       |
| 32      |  (3)  | Section 1350 Certification                                                                                                                                                                                                                                                  |
| 101.INS |  (3)  | XBRL Instance Document                                                                                                                                                                                                                                                      |
| 101.SCH |  (3)  | XBRL Schema Document                                                                                                                                                                                                                                                        |
| 101.CAL |  (3)  | XBRL Calculation Linkbase Document                                                                                                                                                                                                                                          |
| 101.DEF |  (3)  | XBRL Definition Linkbase Document                                                                                                                                                                                                                                           |
| 101.LAB |  (3)  | XBRL Label Linkbase Document                                                                                                                                                                                                                                                |
| 101.PRE |  (3)  | XBRL Presentation Linkbase Document                                                                                                                                                                                                                                         |
|    |       |                                                                                                                                                                                                                                                                        |
| *       |       | Certain portions of this exhibit have been omitted by redacting a portion of the text (indicated by asterisks in the text).  This exhibit has been filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. |
| (1)     |       | Filed herewith                                                                                                                                                                                                                                                              |
| (2)     |       | Previously filed with the Original Filing.                                                                                                                                                                                                                                  |
| (3)     |       | Previously furnished with the Original Filing.                                                                                                                                                                                                                              |

----

|                |                                                                                                                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------|
| Date: June 27, 2014 | BIORESTORATIVE THERAPIES, INC.                                                                                                         |
|                |                                                                                                                                   |
|                | By: /s/ Mark Weinreb      Mark WeinrebChief Executive Officer(Principal Executive and Financial Officer) |
|                |                                                                                                                                   |